Stock Analiz

Organogenesis Holdings Inc. ORGO

Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026

$0.81Market cap $105M
Open the interactive analysis →

Organogenesis Holdings Inc. (ORGO) is a healthcare company listed in the US with a market value of about $105M. In the twelve months to September 30, 2026 it had revenue of $352M and net income of -$135M, a net margin of -38.4%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 11% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% below the current price.

About Organogenesis

Organogenesis is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. Revenue went from $139M in 2016 to $564M in 2025, growth of about 16.9% a year. It was profitable in 6 of the last 10 years in our data. It spends 8% of revenue on research and development.

Score: 1.8 / 5

Value0/5
Future growth3/5
Track record2/5
Financial health2/5
Shareholder returns2/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Profitable 5 years in a row
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.3
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-0.1%
Shareholder yield0.0%
Intrinsic value vs. price−30%

Growth and quality

Revenue growth (1 yr)17.0%
Revenue growth (5 yrs, per year)10.8%
EPS growth (5 yrs, per year)0.0%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)6.3%
ROIC (5-yr avg.)6.3%
Profitable years (of last 10)6
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$352M$564M$482M$433M$451M$467M$338M$261M$193M$199M$139M
Net income-$135M$37M$861000$5M$16M$94M$17M-$39M-$65M-$8M-$17M
Free cash flow-$64000-$24M$4M$7M-$9M$31M-$12M-$40M-$62M-$6M-$6M
EPS (diluted)$-1.19$0.30$-0.01$0.04$0.12$0.70$0.15$-0.42$-0.94$-0.14$-0.27
Net margin-38.4%6.6%0.2%1.1%3.4%20.2%5.1%-14.8%-33.5%-4.2%-12.2%
ROIC—9.8%-0.2%2.5%4.4%15.2%11.4%-23.2%-73.0%-7.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Organogenesis stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 30% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Organogenesis pay a dividend?

Not currently.

Is Organogenesis a good stock to buy?

We do not give buy or sell advice. Organogenesis scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.